NCT06230120

Brief Summary

Chronic pancreatitis leads to severe abdominal pain in up to 70% of patients, and several studies have proposed it has a neuropathic component. Current treatments often fail to provide adequate pain relief, necessitating new innovations for management. Spinal cord stimulation has been proposed to treat severe neuropathic pain refractory to conventional treatment, but sham-controlled trials have not previously been done in patients with visceral pain. This study will test the effect of spinal cord stimulation in chronic pancreatitis patients with insufficient pain relief from standard therapies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

January 10, 2024

Completed
20 days until next milestone

First Posted

Study publicly available on registry

January 30, 2024

Completed
Last Updated

January 30, 2024

Status Verified

January 1, 2024

Enrollment Period

2.2 years

First QC Date

January 10, 2024

Last Update Submit

January 19, 2024

Conditions

Keywords

PainChronic PancratitisPancreatitisSpinal Cord Stimulation

Outcome Measures

Primary Outcomes (1)

  • Pain relief

    The difference in pain intensity scores between active and sham stimulations measured using a patient pain diary based on a numeric rating scale where a score of "0" indicated no pain and a score of "10" indicated worst pain imaginable. Pain scores are registered daily for one week prior to intervention and during the two periods of active and sham SCS stimulations.

    At baseline and days 7-10 in each stimulation period

Secondary Outcomes (5)

  • Patient Global Impression of Change (PGIC)

    Immediately after the intervention

  • The modified Brief Pain Inventory short-form (mBPI-sf)

    At baseline an immediately after the intervention

  • Comprehensive Pain Assessment Tool short-form (COMPAT-sf)

    At baseline an immediately after the intervention

  • Quality of life using SF 36 (short form 36 health survey)

    At baseline an immediately after the intervention

  • Symptoms of depression and anxiety as documented by the Hospital Anxiety and Depression Scale (HADS)

    At baseline an immediately after the intervention

Other Outcomes (4)

  • Quantitative sensory testing: Pressure algometry

    At baseline an immediately after the intervention

  • Quantitative sensory testing: Repetitive pinprick stimulation

    At baseline an immediately after the intervention

  • Quantitative sensory testing: Cold pressor test

    At baseline an immediately after the intervention

  • +1 more other outcomes

Study Arms (2)

Spinal Cord Stimulation

EXPERIMENTAL

A stimulation electrode is placed in the epidural space between the T4-T7 spinal levels and connected to an external electrical pulse generator, which is used for stimulation. The stimulus intensity is initially increased in a ramp-like fashion using high-frequency stimulation at 1000 Hz, with pulse widths of 90 microseconds and intensities increasing from 2 to 14 mA to establish the sensation threshold. After establishing the sensation threshold, the 75 % subthreshold of sensation is used as the stimulation intensity during the active stimulation period.

Device: Spinal Cord Stimulation

Sham

SHAM COMPARATOR

For sham treatment, a similar procedure for establishing the sensation threshold is used, and stimulation at the 75 % subthreshold intensity is initiated, but the stimulation device is turned off 30 seconds after the sensation subthreshold is established.

Device: Sham

Interventions

Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) External electrical pulse generator (Wireless External Neurostimulator System (WENS), Medtronic)

Spinal Cord Stimulation
ShamDEVICE

Stimulation electrode tip (Vectris™ SureScan MRI percutaneous lead, Medtronic Inc, Minneapolis, US) with external stimulator turned off

Sham

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chronic pancreatitis according to the M-ANNHEIM criteria
  • Chronic abdominal pain (pain 3=3days per week in at least 3 months)
  • Pain insuficiently treated with patients ussual analgesic treatment
  • Patients with signs of obstruction of the pancreatic duct due to a stricture or stone have to undergo endoscopic or surgical decompression prior to enrolment

You may not qualify if:

  • Patients suffering from painful conditions other than chronic pancreatitis that made them unable to distinguish the pain associated with chronic pancreatitis
  • Patients with ongoing alcohol abuse and illegal drug dependencies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Gastroenterology, Aalborg University Hospital

Aalborg, 9000, Denmark

Location

MeSH Terms

Conditions

Pancreatitis, ChronicChronic PainPainPancreatitis

Interventions

Spinal Cord Stimulation

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitation

Study Officials

  • Helga A Gulisano, MD

    Aalborg University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

January 10, 2024

First Posted

January 30, 2024

Study Start

November 1, 2020

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

January 30, 2024

Record last verified: 2024-01

Locations